ELISA/assay

Human Amyloid beta Protein 42 ELISA Kit

MBS726927

48-Strip-Wells-(Competitive)

440 USD

ELISA Kit

Human Amyloid beta Protein 42 ELISA Kit

[Amyloid beta Protein 42]

[Human Amyloid b Protein 42 ELISA Kit]

[Amyloid beta A4 protein; Amyloid beta A4 protein; amyloid beta A4 protein; preA4; protease nexin-II; peptidase nexin-II; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); alzheimer disease amyloid protein; cerebral vascular amyloid peptide; amyloid beta (A4) precursor protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II]

[Abeta42]

[Ab42]

[APP; APP; AAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma; A4; AD1; APP; CVAP; PN-II; S-APP-alpha; S-APP-beta; AICD-59; AID(59); AICD-57; AID(57); AICD-50; AID(50)]

A4_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of Abeta40. No significant cross-reactivity or interference between Abeta40 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between Abeta40 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Cell Culture Supernatants, Body Fluid And Tissue Homogenate. Assay Type: Quantitative Competitive. Sensitivity: 1.0 pg/mL.

Neurobiology

Intended Uses: This Abeta40 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat Abeta40. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: Abeta40 ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-Abeta40 antibody and an Abeta40-HRP conjugate. The assay sample and buffer are incubated together with Abeta40-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the Abeta40 concentration since Abeta40 from samples and Abeta40-HRP conjugate compete for the anti-Abeta40 antibody binding site. Since the number of sites is limited, as more sites are occupied by Abeta40 from the sample, fewer sites are left to bind Abeta40-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The Abeta40 concentration in each sample is interpolated from this standard curve.

112927

P05067.3

84,521 Da

Activated TLR4 Signalling Pathway (106400); Advanced Glycosylation Endproduct Receptor Signaling Pathway (187092); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Caspase Cascade In Apoptosis Pathway (137974); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Cytosolic Sensors Of Pathogen-associated DNA Pathway (576255); DEx/H-box Helicases Activate Type I IFN And Inflammatory Cytokines Production Pathway (833822)

This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Aug 2014]

APP: a cell surface receptor that influences neurite growth, neuronal adhesion and axonogenesis. Cleaved by secretases to form a number of peptides, some of which bind to the acetyltransferase complex Fe65/TIP60 to promote transcriptional activation. The Abeta peptide is released from the cell, its extracellular deposition and accumulation form the main components of amyloid plaques in Alzheimer s disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis. Can promote transcription activation through binding to Fe65-Tip60 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(O) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. Induces a RAGE-dependent pathway that activates p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, JIP1, SHC1 and, NUMB and DAB1. Binding to DAB1 inhibits its serine phosphorylation. Associates with microtubules in the presence of ATP and in a kinesin-dependent manner. Amyloid beta-42 binds nAChRA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex- opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra- striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. 10 isoforms of the human protein are produced by alternative splicing. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non- neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Belongs to the APP family. Protein type: Apoptosis; Cell surface; Membrane protein, integral; Transcription factor; Receptor, misc. Chromosomal Location of Human Ortholog: 21q21.3. Cellular Component: Golgi apparatus; extracellular space; cell surface; integral to plasma membrane; integral to membrane; coated pit; intercellular junction; cytosol; ER to Golgi transport vesicle; lipid raft; ciliary rootlet; perinuclear region of cytoplasm; nuclear envelope lumen; cytoplasm; synapse; dendritic shaft; neuromuscular junction; receptor complex; endosome; intracellular membrane-bound organelle; extracellular region; dendritic spine; axon; apical part of cell; plasma membrane; spindle midzone. Molecular Function: serine-type endopeptidase inhibitor activity; heparin binding; identical protein binding; protein binding; protease activator activity; enzyme binding; DNA binding; transition metal ion binding; PTB domain binding; acetylcholine receptor binding; receptor binding. Biological Process: extracellular matrix organization and biogenesis; adult locomotory behavior; mRNA polyadenylation; locomotory behavior; positive regulation of mitotic cell cycle; protein amino acid phosphorylation; regulation of translation; platelet degranulation; synaptic growth at neuromuscular junction; forebrain development; dendrite development; collateral sprouting in the absence of injury; visual learning; neuromuscular process controlling balance; cell adhesion; neurite development; platelet activation; cholesterol metabolic process; Notch signaling pathway; cellular copper ion homeostasis; regulation of epidermal growth factor receptor activity; mating behavior; axon cargo transport; regulation of multicellular organism growth; endocytosis; axon midline choice point recognition; smooth endoplasmic reticulum calcium ion homeostasis; neuron apoptosis; negative regulation of neuron differentiation; suckling behavior; axonogenesis; ionotropic glutamate receptor signaling pathway; regulation of synapse structure and activity; regulation of protein binding; innate immune response; positive regulation of transcription from RNA polymerase II promoter; response to oxidative stress; blood coagulation; neuron remodeling. Disease: Alzheimer Disease

48-Strip-Wells-(Competitive)

440 USD

48-Strip-Wells-(Sandwich)

440

96-Strip-Wells-(Competitive)

640

96-Strip-Wells-(Sandwich)

640

5x96-Strip-Wells-(Competitive)

2895

5x96-Strip-Wells-(Sandwich)

2895

10x96-Strip-Wells-(Competitive)

5415

10x96-Strip-Wells-(Sandwich)

5415